Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Explore private companies / Convergent Therapeutics IPO
Convergent Therapeutics

Convergent Therapeutics IPO

$269.38MM
Series A-4 Valuation, Sep 2024
Register for details
For more details on financing and valuation for Convergent Therapeutics, register or log in.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Convergent Therapeutics IPO date and status

2020
Founded
IPO Mentioned
Confidential Filing
S-1 Filed
IPO

Company details

Convergent Therapeutics is a pharmaceutical company with a mission to target and treat cancer through radiotherapies. Aiming to create therapies for prostate cancer, the company’s CONV01-α treatment is being explored in addition to other common cancer treatments including chemotherapy, hormone therapy, and immunotherapy. Convergent Therapeutics was founded in 2021 by Neil Bander and Philip Kantoff and is headquartered in Cambridge, MA.
Founded
2020
Headquarters
Cambridge, MA, United States
Forge Price 1
Price not yet available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$269.38MM
Total Funding
$130MM
Last Funding Round
Series A-4

Learn more about Convergent Therapeutics

To invest in Convergent Therapeutics pre-IPO

Can you invest in Convergent Therapeutics pre-IPO?

Convergent Therapeutics is privately held and not traded on public markets, so pre-IPO investments are available only to accredited investors.

If you’re already accredited and have completed Forge’s verification, you can visit our marketplace to review and invest in private companies ahead of an IPO.

If you haven’t yet completed your accredited investor verification with Forge, you can start that process now to unlock access to new private-company offerings.

For more on who qualifies—and how to get verified—see our blog “Accredited investors, qualified clients and qualified purchasers: Who can invest?

Can you sell shares of Convergent Therapeutics before it goes public?

Yes, subject to any contractual or corporate transfer restrictions, it is possible to list your shares to sell while Convergent Therapeutics is still private. If you’re considering selling, you can register today for free to get started. Once registered, you can evaluate pricing insights and market activity to inform your decision, then post your shares for sale and set the terms, like quantity and price—all directly through our platform.

If you’d like additional guidance at any point, Forge private market specialists are available to help. For a step-by-step overview, check out our seller’s guide.

What is the pre-IPO value of my Convergent Therapeutics shares?

To explore the value of your Convergent Therapeutics shares, create a free account to access Forge’s marketplace. Once inside, you’ll find several pricing insights to help guide your decision—these include historical transaction data, a live order book showing current buy and sell interest, and Forge Price™, a derived, indicative price based on recent transactions, investor activity, and other relevant market data.

These insights can help you determine a price you’re comfortable with if you choose to sell your shares. If you’d like additional guidance along the way, Forge private market specialists are available to help. You can also review our seller’s guide for a step-by-step overview.

Is Convergent Therapeutics a publicly traded company?

Convergent Therapeutics is a private company and not publicly traded.

If you’re interested in buying or selling shares in private companies, you can register with Forge today for free to explore available opportunities. Once registered, you’ll gain access to our marketplace, where you can view active buy and sell interest, evaluate pricing signals and take action directly through the platform.

To learn more about Convergent Therapeutics potential IPO

Will Convergent Therapeutics go IPO?

Convergent Therapeutics has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2025.

What is Convergent Therapeutics’ IPO price?

The Convergent Therapeutics IPO price does not exist at this time, as Convergent Therapeutics is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Convergent Therapeutics, register for Forge today.

When was Convergent Therapeutics founded?

Convergent Therapeutics was founded in 2020.

What is Convergent Therapeutics funding to date?

Convergent Therapeutics has raised $130MM to date.

Convergent Therapeutics pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
09/24/2024 Series A-4 $40MM $2.01 $269.38MM Novo Holdings
Price per Share
$ xx.xx
Shares Outstanding
19,898,516
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Novo Holdings
05/03/2023 Series A-1 $81.68MM $1.55 $186.01MM Orbimed, Ra Capital Management, The Invus Group
Price per Share
$ xx.xx
Shares Outstanding
52,821,240
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Ra Capital Management, The Invus Group
05/03/2023 Series A-2 $3.14MM $1.24 $186.01MM Orbimed, Ra Capital Management, The Invus Group
Price per Share
$ xx.xx
Shares Outstanding
2,542,409
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Ra Capital Management, The Invus Group
05/03/2023 Series A-3 $5.18MM $1.08 $186.01MM Orbimed, Ra Capital Management, The Invus Group
Price per Share
$ xx.xx
Shares Outstanding
4,783,404
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Ra Capital Management, The Invus Group

Convergent Therapeutics IPO news and media highlights

Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Convergent Therapeutics hired Richard Messmann as chief medical officer.

Convergent Therapeutics: $40 Million (Series A Extension) Secured From Novo

Convergent Therapeutics, a clinical stage biotech focused on radiopharmaceutical cancer therapies, secured $40 million in Series A funding from Novo Holdings. The funds will support Convergent's prostate cancer drug CONV01-α, now in Phase II trials, and radiopharmaceutical pipeline. Convergent also added Novo's Jim Trenkle to its board and oncology veteran Richard Messmann as CMO.

NorthStar and Convergent expand deal for prostate cancer drug

NorthStar Medical Radioisotopes and Convergent Therapeutics are expanding their collaboration to develop CONV01-α, a prostate cancer drug combining Convergent's prostate-specific antibody with NorthStar's Ac-225 radioisotope. NorthStar will supply Ac-225 and manufacture CONV01-α for Convergent's clinical trials under the agreement.

Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff

Philip Kantoff discusses radiopharmaceuticals for cancer treatment, highlighting promising results for antibody-based PSMA therapies using actinium-225. He envisions radiopharmaceuticals playing a major role over the next 5-10 years, with potential for curative approaches in early cancers. Kantoff emphasizes the need for greater biological understanding to optimize radiopharmaceutical targeting strategies.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
VeraDermicsVeraDermicsNot available$ xx.xxSeries C$306.13MM$1.27$151MM
Eikon TherapeuticsEikon TherapeuticsNot available$ xx.xxSeries D$1.57B$5.84$326.93MM
Spyglass PharmaSpyglass PharmaNot available$ xx.xxSeries D$350.04MM$2.33$75MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $550.00 +$102.77 (22.98%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx
SambaNova Systems SambaNova Systems $14.74 -$1.36 (8.45%)Medium $xxx.xx

Forge, your trusted partner for pre-IPO insights and Convergent Therapeutics data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.